25-05-2012, 01:38 PM
ANTIMALARIAL MEDICINES FROM MEDICINAL PLANTS OF SOUTHERN AFRICA
ANTI MALARIAL MEDICINE.pdf (Size: 214.28 KB / Downloads: 197)
QUARTERLY REPORT
Work Planned for Completion
• NBI to continue recollections and botanical profiling of promising
taxa.
• Further fieldtrips to collect extra chemotypes in support of
agroprocessing activities.
• Submission of extracts of Ref 2, Ref 11, Ref 25, Ref 26 and Ref
29 for antiplasmodial in vivo assaying.
• Continue with structure elucidation of pure compounds from
active fractions of P01609-1A (Ref 2). Targeted isolation and
identification of other compounds from active fractions.
• Reverse-phase preparative liquid chromatography of active band
(MAL-II-22K) of P00601-2B (Ref 11) to isolate and identify active
compounds.
• Continue with purification and identification of active compounds
from dichloromethane fraction of P05644-1B (Ref 25).
• Continue with targeted purification of active bands/compounds
from P05633-1B (Ref 26).
• Continue with purification of P02424-2B (Ref 29) to isolate and
identify active bands/compounds.
• Two crude extracts, P02424-2B and P00601-2B, were identified
for in vivo testing. These crude extracts have been prepared in
sufficient quantities by the CSIR and have are currently being
tested for in vivo activity at UCT. Six promising extracts were
prioritised for the fractionation and isolation of pure compounds.
Work completed but not planned
• One active compound from P01609-1A (Ref 2), which showed
evidence of cytotoxicity in the CHO assay, has been submitted to
UP for their biochemical evaluation.
• Further investigation of the chloroform extract from sequential
extraction of P00599-1A (Ref 15) using different solvents with
increasing polarity. Reproduced sufficient quantity of this extract
for further fractionation work to see if observed activity improves.
Work planned for the next quarter
• Complete structure elucidation of those compounds isolated
from P01609-1A (Ref 2), which show good antiplasmodial
activity. Those compounds that show cytotoxicty as well will be
considered for SAR (structure-activity relationship) studies.
Summary by Project Leader
A work plan has been completed for conclusion of the programme by the last working
day, 31st December 2003. An agroprocessing plan has been drawn up, within the
terms of the original programme submission, and work on this has commenced.
Funding has been allocated for the purpose. It will be noted from the content of this
report that to date altogether 615 crude extracts and 536 purified fractions have been
tested for in vitro antiplasmodial activity and the most active of these have also been
submitted to cytotoxicity testing to determine their selectivity index.